ReviewFrontiers in immunology2021
Good's Syndrome: Time to Move on From Reviewing the Past.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Good's Syndrome Mirrors a Combined Immunodeficiency with Anti-Cytokine Antibodies in the Total Absence of B Cells.Journal of clinical immunology · 2026Article
- Invasive pulmonary aspergillosis as a sentinel manifestation of good syndrome in a patient with thymoma.IDCases · 2026Article
- CD19, immunoglobulin level, and varied anti-cytokine autoantibodies underline dichotomous susceptibility to types of infection in patients with thymomas.Frontiers in immunology · 2026Article
- Gastrointestinal pathology in Good's syndrome, thinking beyond common variable immunodeficiency: a clinicopathological observation.Virchows Archiv : an international journal of pathology · 2025Article
- Article
- Pure Red Cell Aplasia in a Patient with Thymic Hyperplasia, Hypogammaglobulinemia and Adult T-cell Leukemia/Lymphoma.Internal medicine (Tokyo, Japan) · 2025Article
- Secondary antibody deficiencies in the modern era: emerging trends, diagnostic pitfalls, and advances in personalised management.Frontiers in immunology · 2025Review
- Good's Syndrome Revealed by Recurrent Sigmoid Diverticulitis.European journal of case reports in internal medicine · 2025Article
- Unusual presentation of cytomegalovirus and varicella-zoster virus infection in a patient with good's syndrome: A case report.Radiology case reports · 2024Article
- Thymoma with recurrent opportunistic infections-a case report.Oxford medical case reports · 2024Article
- Oral Diseases as a Manifestation of Inborn Errors of Immunity.Journal of clinical medicine · 2024Review
- Good's syndrome combined with CMV gastroenteritis: A case report and literature review.Clinical case reports · 2024Article
- Article
- Autoimmunity in thymic epithelial tumors: a not yet clarified pathologic paradigm associated with several unmet clinical needs.Frontiers in immunology · 2024Review
- Insights from a Case of Good's Syndrome (Immunodeficiency with Thymoma).Biomedicines · 2023Article
- Good's syndrome and COVID-19: case report and literature review.Mediastinum (Hong Kong, China) · 2023Article
- In-depth blood immune profiling of Good syndrome patients.Frontiers in immunology · 2023Article
- Relapsing cellulitis associated with Campylobacter coli bacteremia in a Good's syndrome patient: a case report.BMC infectious diseases · 2022Article
- Diagnosis of Good Syndrome following Recurrent Coronavirus Disease-2019 Infections.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For seven decades, the pathophysiology of Good's syndrome (GS) has remained a mystery, with few attempts to solve it. Initially described as an association between hypogammaglobulinemia and thymoma, controversy exists whether this is a unique disease, or a subgroup of Common Variable Immune Deficiency (CVID). Recently, some distinguishing aspects of both syndromes have come to light reflecting fundamental differences in their underlying pathophysiology. GS and CVID differ in demographic features and immune phenotype. GS is found almost exclusively in adults and is characterized by a significantly reduced or absence of peripheral B cells. In CVID, which also occurs in children, most patients have normal or slightly reduced peripheral B cells, with a distinguishing feature of low memory B cells. Similarly, differences in T cell dysregulation and manifestations of hematologic cytopenias may further distinguish GS from CVID. Knowledge of the clinical phenotype of this rare adult immune deficiency stems from individual case reports, retrospective, and cross-sectional data on a few cohorts with a limited number of well characterized patients. The understanding of pathophysiology in GS is hampered by the incomplete and inconsistent reporting of clinical and laboratory data, with a limited knowledge of its natural history. In this mini review, we discuss current state of the art data and identify research gaps. In order to resolve controversies and fill in knowledge gaps, we propose a coordinated paradigm shift from incidence reporting to robust investigative studies, addressing mechanisms of disease. We hope this novel approach sets a clear direction to solve the current controversies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.